Tim Kutzkey bought $604K of Surrozen (SRZN)
Executed Dec 5 2025, disclosed Dec 8 2025, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Dec 8 2025), the stock returned -3.7% (delay-adjusted); from the execution session (Dec 5 2025), +7.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Tim Kutzkey (Director) filed 5 Form 4 reports in the trailing twelve months (5 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in Surrozen, Inc. (SRZN). Across 5 priced purchase filings, the average 21-session return was +35.4% from execution and +20.0% from disclosure (delay-adjusted; derived). The largest single filing was $4.0M of SRZN (315,457 sh across 2 lots, as filed), executed Nov 13 2025.
Healthcare · Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→29,945 sh across 4 lots
Exec Jan 15
Filed Jan 20 · 7:31 PM ET SRZNPURCHASE Surrozen, Inc. $247K
12,470 sh across 2 lots
Exec Jan 13
Filed Jan 15 · 4:11 PM ET SRZNPURCHASE Surrozen, Inc. $300K
15,100 sh across 2 lots
Exec Jan 6
Filed Jan 8 · 5:19 PM ET SRZNPURCHASE Surrozen, Inc. $4.0M
315,457 sh across 2 lots
Exec Nov 13 2025
Filed Dec 2 2025 · 9:36 PM ET †